HTFL Heartflow, Inc.
XNAS
57.48
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
HTFL
$57.48
—
What changed
Recent filings, trades and movesKey stats
$57.48
- 52-Week Range
- $20.13 – $60.56
- YTD
- +98.42%
- IV Rank (30D)
- 100.0
- Straddle Price
- $15.50
- P/C Vol Ratio
- 1.45
- Market Cap
- $4.9B
- Open
- $56.61
- Day Range
- $56.61 – $58.30
- Volume
- 130,710
- Prev Close
- $55.80
Fair Value
MODEL: LONG
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 4.86% |
| Beta vs SPY | 1.48 |
| Cost of Equity (CAPM) | 13.03% (VRP-adj) |
| WACC | 12.77% |
| Volatility Risk Premium | +48.4pp (IV − HV30), ERP adj +50bps |
| Effective Tax Rate | 21.0% |
| Rev. Growth (YoY, DCF input) | +3.0% |
| DCF Horizon | 10 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.03 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $-0.1B |
| Return on Equity (TTM) | -42.3% |
| Book / Price | 6.0% |
| Gross Margin (TTM) | 78.1% |
| FCF Margin (TTM) | -30.9% |
| Debt / Equity | 0.00 |
| Quality Score | 2/6 — normal (10y DCF) |
| SMA 50 | $51.57 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $54.95 |
| Bollinger Width / SMA20 | 23.6% (drives anchor stability) |
| Net Debt | $-0.0B |
| Market Cap | $5B |
Peers used for multiples: DXCM, GH, ISRG, NTRA, OSCR, RMD, RVMD, TWST
60-Day Conviction
67%
20-Day Fair Value
≈ by Dec 10, 2026
$58.22
α +1.2%
rank 51%
conviction
78%
40-Day Fair Value
≈ by Jan 8, 2027
$58.83
α +2.3%
rank 22%
conviction
70%
60-Day Fair Value
≈ by Feb 8, 2027
$59.09
α +2.8%
rank 24%
conviction
67%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | n/a | 0% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | n/a | 0% | median 25.7× · 4 peers |
| Peer EV/EBITDA | n/a | 0% | median 17.9× · 4 peers |
| Peer P/B | $39.80 | 19% | median 11.9× · 7 peers |
| Peer P/S | $34.26 | 19% | median 14.9× · 8 peers |
| Market Anchor (SMA50) | $51.57 | 31% | stability 32% (BB-width) |
| Options Expected (B-L 30d) | $54.57 | 31% | 13 strikes · skew +0.12 |
As of 2026-11-11 · updated
Related
About
- Industry (SIC)
- SURGICAL & MEDICAL INSTRUMENTS & APPARATUS (3841) · industry map
- Exchange
- XNAS
- Market Cap
- $4.9B
- Employees
- 843
- List Date
- 2025-08-08
- CIK
- 0001464521
- Next Earnings
- 2026-11-12 (After-Close)
- EPS Forecast
- ($0.10)
- Headquarters
- San Francisco, CA
- Homepage
- https://www.heartflow.com
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis,…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '25 | '26 | Avg |
|---|---|---|---|
| Jan | -- | 3.11% | 3.11% |
| Feb | -- | -19.53% | -19.53% |
| Mar | -- | 1.16% | 1.16% |
| Apr | -- | 21.47% | 21.47% |
| May | -- | 8.06% | 8.06% |
| Jun | -- | -5.35% | -5.35% |
| Jul | -- | -16.47% | -16.47% |
| Aug | 9.57% | 88.30% | 48.94% |
| Sep | 8.02% | -1.35% | 3.33% |
| Oct | 3.45% | 20.73% | 12.09% |
| Nov | -5.27% | 5.38%* | 0.06% |
| Dec | -3.32% | -- | -3.32% |
| Total | 12.14% | 105.86% | 59.00% |
* Only 2 year(s) of data available.
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $55.33
SMA 50: $51.70
SMA 200: $34.97
Current: $57.10
EMA 12: $55.51
EMA 26: $54.14
MACD: 1.3691 | Signal: -0.3104
BULLISH
ADX (14): 18.95
RANGE
+DI: 22.78
−DI: 16.89
Momentum Oscillators
RSI (14): 56.93
NEUTRAL
Stoch %K: 57.47
Stoch %D: 44.10
Williams %R: -36.42
Volume & Volatility
BB Upper: $61.37
BB Lower: $49.29
NEUTRAL
OBV: 62,107,987
Vol SMA 20: 1,524,783
Vol ROC: -93.41%
ATR: $3.16
True Range: $2.50
HV 20: 70.7%
HV 30: 63.9%
HV 60: 55.4%
Data Summary
Data Points: 317
Last Updated:
Date Range: 2025-08-08T00:00:00 – 2026-11-10T00:00:00
AI Analysis
Written before HTFL’s Aug 13 earnings report, so it doesn’t reflect the results.
LLM Stock Analysis Report: HTFL
Executive Summary
Overall Assessment: BEARISH (Confidence Level: 6/10)
Key Drivers and Primary Risks:
- Technical indicators suggest a bearish trend, with MACD indicating a sell signal.
- Volatility is high, reflecting market uncertainty.
- Recent negative news headlines have contributed to the bearish sentiment.
Investment Thesis: HTFL's recent slowdown has led to a decline in stock price. The company faces challenges in regaining its momentum, given the current market environment and competition. A thorough risk assessment is necessary before considering investment opportunities.
Recent News Sentiment Impact: The negative news headlines from BioWorld MedTech have contributed to the bearish sentiment, with a 6 out of 10 confidence level.
Technical Analysis
Trend Direction:
- Short-term (1-4 weeks): BEARISH
- Medium-term (1-3 months): NEUTRAL
- Long-term (3-12 months): BEARISH
Support/Resistance Levels: SMA 20 ($35.44) and SMA 50 ($34.60) act as key resistance levels.
Momentum Signals:
- RSI (14): 33.08 (neutral)
- MACD: -0.94 / Signal: -0.80 / Histogram: -0.14 (bearish)
Volume Analysis:
- Volume SMA 20: 364021.55
- On-Balance Volume (OBV): 12835357.00
- Volume Rate of Change: 140.95%
News & Sentiment Analysis
Recent Headlines Summary: Negative news headlines from BioWorld MedTech and mixed market commentary have dominated the recent news cycle.
Sentiment Assessment: NEGATIVE
Catalyst Identification: No upcoming earnings or major events are scheduled, but investors will be monitoring developments in the med-tech industry for potential catalysts.
Market Narrative: The negative sentiment has been driven by recent news headlines and a decline in technical indicators. A turnaround will require a significant shift in market dynamics or positive fundamental changes.
Risk & Volatility Assessment
Beta Interpretation: High risk relative to the market (beta > 1.2), indicating increased volatility.
Volatility Regime: Current volatility is higher than historical levels, reflecting market uncertainty.
Options Market Signals: No options data available due to a lack of recent activity.
Downside Protection: Support levels include SMA 20 ($35.44) and SMA 50 ($34.60). Risk management considerations involve setting stop-loss levels around these support levels.
Market Context & Positioning
Sector Performance: The med-tech sector has experienced a decline in performance, contributing to the bearish sentiment.
Institutional Activity: No recent institutional activity is visible in the options market or trading volume.
Correlation Analysis: HTFL's movement is inversely correlated with the market (R-squared interpretation).
Relative Valuation: The stock is relatively undervalued compared to its peers and sector.
Key Levels & Action Items
Critical Price Levels: SMA 20 ($35.44) and SMA 50 ($34.60) act as key resistance levels.
Breakout/Breakdown Levels: A breakout above $35.44 or a breakdown below $29.71 could trigger significant price movements.
Time-Sensitive Catalysts: No immediate catalysts are scheduled, but investors will be monitoring developments in the med-tech industry for potential catalysts.
Risk Management: Stop-loss levels should be set around the support levels of SMA 20 ($35.44) and SMA 50 ($34.60). Position sizing considerations involve a balanced risk-reward approach given the high volatility.
Generated
News
All HTFL news →
Earnings History
3 of 3 under expected move
Avg Expected Move
20.08%
Avg Actual Move
5.90%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2026-03-18 | After-Close | 25.81% | 1.65% | 0.06x | Within |
| 2026-05-14 | After-Close | 16.52% | 12.17% | 0.74x | Within |
| 2026-08-13 | Pre-Market | 17.92% | 3.89% | 0.22x | Within |
Earnings calendar: this week’s reports with expected vs actual moves →
HTFL Options Activity & IV Rank
HTFL IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 109.7%
7-DTE IV: 156.4%
Expected Move: $15.50
7-DTE Move: $11.85
Days to Exp: 37 (2026-12-18)
Options Flow · All expiries
Call Volume: 414
Put Volume: 601
P/C Volume: 1.452
BEARISH
Call OI: 6,581
Put OI: 12,171
P/C OI: 1.849
Total OI: 18,752
ATM Options Pricing
ATM Call: $8.80
ATM Put: $6.70
Call %: 15.3%
Put %: 11.7%
Chain Summary
Chain Volume: 1,015
Chain OI: 18,752
Last Updated: 11/11/2026
Spread Scanner
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Calendars: the long leg is valued at the short leg’s expiration (Black-Scholes at its current IV) across the range of prices the short leg’s IV implies, giving the best-case profit (R/R = that over the debit) and P(profit).
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Scanning bull put, bear call, iron condor and calendar spreads…
Dealer Positioning
LOW γ vs HISTORY
Estimated net dealer gamma is at the 6th percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
6%
vs own history
GEX tilt
-0.43
OI-weighted, today
Vanna tilt
+0.71
δ-sensitivity to IV
Charm tilt
-0.86
δ-decay vs time
Vanna tilt +0.71: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.86: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 18 ATM contracts, 13k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
—
—
pts
EXTREME
No data
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Loading the implied volatility surface…
Volatility Smile
Loading the implied volatility smile…
IV Rank (7 DTE)53.9MediumNov 11
IV Rank (30 DTE)100.0HighNov 11
Straddle Price (30 DTE)$15.50Nov 11
Beta Analysis
Risk Metrics
Beta: 1.9464
Alpha: 60.07%
Correlation: 0.3408
R-Squared: 11.6%
Stock Volatility: 78.2%
Market Volatility: 13.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
High volatility - stock moves more than market
High volatility - stock moves more than market
Beta & Alpha Over Time
Notable investors who own HTFL
4 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Point72 Hedge fund Steve Cohen | $50.5M | #325 of 1945 | +219.7% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $27.1M | #940 of 3716 | -15.6% | 13F | |
| Citadel Hedge fund Ken Griffin | $23.5M | #1050 of 6285 | +5.7% | 13F | |
| Renaissance Technologies Hedge fund Jim Simons | $11.2M | #996 of 3138 | new | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
HTFL Institutional Ownership (13F)
Filings for 2026-06-30 · 81 already for 2026-09-30
? 13F Guide
Diluted shares outstanding: 44,479,152 (as of 2026-03-31)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
5 filers$6.98M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $2.24M | 32.13% | 2026-06-30 |
| 2 | IMC-Chicago, LLC Custodian | $2.24M | 32.09% | 2026-09-30 |
| 3 | Citadel Advisors LLC Custodian | $1.06M | 15.14% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $727.63K | 10.43% | 2026-06-30 |
| 5 | Simplex Trading, LLC Custodian | $711.42K | 10.20% | 2026-09-30 |
4 filers$1.99M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $1.07M | 53.89% | 2026-06-30 |
| 2 | IMC-Chicago, LLC Custodian | $532.33K | 26.79% | 2026-09-30 |
| 3 | Citadel Advisors LLC Custodian | $299.27K | 15.06% | 2026-06-30 |
| 4 | Simplex Trading, LLC Custodian | $84.58K | 4.26% | 2026-09-30 |
HTFL Insider Trading (Form 4)
Latest: 2026-11-10Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-11-10 | Marie L. Jones | Chief Accounting Officer | Mixed Tax −568 · Grant +795 |
+227 | $33.33 | -$14.1K | EDGAR |
| 2026-11-10 | John C.M. Farquhar | Chief Executive Officer | Mixed Sell −38,900 · Tax −7,751 · Exer +15,620 |
−31,031 | $41.90 | -$2.54M | EDGAR |
| 2026-11-10 | Vikram Verghese | Chief Financial Officer | Mixed Sell −3,587 · Tax −2,009 |
−5,596 | $52.88 | -$295.9K | EDGAR |
| 2026-11-10 | Campbell Rogers | Chief Medical Officer | Tax (F) | −2,270 | $52.40 | -$118.9K | EDGAR |
| 2026-10-26 | Campbell Rogers | Chief Medical Officer | Mixed Sell −23,933 · Exer +17,430 |
−6,503 | $34.59 | -$1.20M | EDGAR |
| 2026-10-14 | John C.M. Farquhar | Chief Executive Officer | Sell (S) | −38,900 | $49.57 | -$1.93M | EDGAR |
| 2026-09-21 | Campbell Rogers | Chief Medical Officer | Mixed Exer +13,179 · Sell −19,682 |
−6,503 | $33.22 | -$882.5K | EDGAR |
| 2026-09-18 | Vikram Verghese | Chief Financial Officer | Sell (S) | −24,345 | $50.55 | -$1.23M | EDGAR |
| 2026-09-15 | Vikram Verghese | Chief Financial Officer | Sell (S) | −34,975 | $50.08 | -$1.75M | EDGAR |
| 2026-09-14 | John C.M. Farquhar | Chief Executive Officer | Sell (S) | −38,900 | $46.78 | -$1.82M | EDGAR |
| 2026-09-10 | Vikram Verghese | Chief Financial Officer | Sell (S) | −6,640 | $50.03 | -$332.2K | EDGAR |
| 2026-09-04 | Vikram Verghese | Chief Financial Officer | Sell (S) | −33,416 | $49.85 | -$1.67M | EDGAR |
| 2026-08-25 | John C.M. Farquhar | Chief Executive Officer | Sell (S) | −27,230 | $50.00 | -$1.36M | EDGAR |
| 2026-08-20 | John C.M. Farquhar | Chief Executive Officer | Sell (S) | −32,676 | $45.00 | -$1.47M | EDGAR |
| 2026-08-19 | Campbell Rogers | Chief Medical Officer | Mixed Exer +9,219 · Sell −9,219 |
— | $30.11 | -$204.9K | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
HTFL Insider Holdings
12 insiders · @ $57.10
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Bain Capital Life Sciences Fund III, L.P. | 10%+ Owner | 12,448,158 | $710.79M | $0 | 1 | 2025-08-13 |
| 2 | Bain Capital Life Sciences Investors, LLC | 10%+ Owner | 10,448,158 | $596.59M | -$56.10M | 1 | 2026-02-06 |
| 3 | Casey M Tansey | Director | 3,089,206 | $176.39M | $0 | 2 | 2026-06-18 |
| 4 | Jeffrey C Lightcap | Director | 1,542,620 | $88.08M | $1.05M | 5 | 2026-07-28 |
| 5 | HCPCIV 1, LLC | 10%+ Owner | 833,075 | $47.57M | $0 | 1 | 2025-08-22 |
| 6 | John C.M. Farquhar | Chief Executive Officer | 283,014 | $16.16M | -$12.87M | 19 | 2026-10-14 |
| 7 | William C Weldon | Director | 209,685 | $11.97M | $0 | 3 | 2026-07-10 |
| 8 | Timothy C Barabe | Director | 188,231 | $10.75M | $0 | 6 | 2026-07-24 |
| 9 | Vikram Verghese | Chief Financial Officer | 171,949 | $9.82M | -$4.98M | 11 | 2026-09-18 |
| 10 | Campbell Rogers | Chief Medical Officer | 148,140 | $8.46M | -$8.03M | 14 | 2026-10-26 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
HTFL Board & Officers
As of SEC filings through Nov 10, 2026Directors 9
- Casey M Tansey · since Aug 7, 2025
- Jeffrey C Lightcap · since Aug 7, 2025
- John C.M. Farquhar · since Aug 7, 2025
- Julie A Cullivan · since Aug 7, 2025
- Nicholas Downing · since Aug 7, 2025
- Timothy C Barabe · since Aug 7, 2025
- Wayne Joseph Riley · since Aug 7, 2025
- William C Weldon · since Aug 7, 2025
- HealthCor Partners Management LP (entity) · listed since Mar 2026
Officers 4
- John C.M. Farquhar · Chief Executive Officer · since Aug 7, 2025
- Vikram Verghese · Chief Financial Officer · since Aug 7, 2025
- Campbell Rogers · Chief Medical Officer · since Aug 7, 2025
- Marie L. Jones · Chief Accounting Officer · listed since May 2026
Changes in the last 10 years (38)
| May 8, 2026 | Marie L. Jones listed as Chief Accounting Officer (previously Chief Accounting Officer, VP) in SEC filings |
| Apr 30, 2026 | Bain Capital Life Sciences Investors, LLC reported in an SEC filing no longer being a 10% owner |
| Apr 30, 2026 | Bain Capital Life Sciences III General Partner, LLC reported in an SEC filing no longer being a 10% owner |
| Apr 30, 2026 | Bain Capital Life Sciences Fund III, L.P. reported in an SEC filing no longer being a 10% owner |
| Apr 30, 2026 | BCLS Fund III Investments, LP reported in an SEC filing no longer being a 10% owner |
| Apr 30, 2026 | BCLS Fund III Investments GP, LLC reported in an SEC filing no longer being a 10% owner |
| Mar 26, 2026 | HealthCor Partners Management LP first listed as a director in an SEC filing |
| Aug 22, 2025 | HealthCor Partners Management LP reported in an SEC filing no longer being a 10% owner |
| Aug 22, 2025 | HealthCor Partners LP reported in an SEC filing no longer being a 10% owner |
| Aug 22, 2025 | HealthCor Partners II, L.P. reported in an SEC filing no longer being a 10% owner |
| Aug 22, 2025 | HealthCor Partners GP, LLC reported in an SEC filing no longer being a 10% owner |
| Aug 22, 2025 | HealthCor Partners Fund LP reported in an SEC filing no longer being a 10% owner |
| Aug 22, 2025 | HealthCor Partners Fund II, L.P. reported in an SEC filing no longer being a 10% owner |
| Aug 22, 2025 | Hcpciv 1, LLC reported in an SEC filing no longer being a 10% owner |
| Aug 7, 2025 | William C Weldon became a director |
| Aug 7, 2025 | Wayne Joseph Riley became a director |
| Aug 7, 2025 | Vikram Verghese became Chief Financial Officer |
| Aug 7, 2025 | Timothy C Barabe became a director |
| Aug 7, 2025 | Nicholas Downing became a director |
| Aug 7, 2025 | Marie L. Jones became Chief Accounting Officer, VP |
| Aug 7, 2025 | Julie A Cullivan became a director |
| Aug 7, 2025 | John C.M. Farquhar became a director |
| Aug 7, 2025 | John C.M. Farquhar became Chief Executive Officer |
| Aug 7, 2025 | Jeffrey C Lightcap became a director |
| Aug 7, 2025 | HealthCor Partners Management LP became a 10% owner |
| Aug 7, 2025 | HealthCor Partners LP became a 10% owner |
| Aug 7, 2025 | HealthCor Partners II, L.P. became a 10% owner |
| Aug 7, 2025 | HealthCor Partners GP, LLC became a 10% owner |
| Aug 7, 2025 | HealthCor Partners Fund LP became a 10% owner |
| Aug 7, 2025 | HealthCor Partners Fund II, L.P. became a 10% owner |
| Aug 7, 2025 | Hcpciv 1, LLC became a 10% owner |
| Aug 7, 2025 | Casey M Tansey became a director |
| Aug 7, 2025 | Campbell Rogers became Chief Medical Officer |
| Aug 7, 2025 | Bain Capital Life Sciences Investors, LLC became a 10% owner |
| Aug 7, 2025 | Bain Capital Life Sciences III General Partner, LLC became a 10% owner |
| Aug 7, 2025 | Bain Capital Life Sciences Fund III, L.P. became a 10% owner |
| Aug 7, 2025 | BCLS Fund III Investments, LP became a 10% owner |
| Aug 7, 2025 | BCLS Fund III Investments GP, LLC became a 10% owner |
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
HTFL Proposed Insider Sales (Form 144)
Latest: 2026-11-10
? Form 144 Guide
Last 30d:
5 filings
· $5.9M notice value
· Last 90d:
22 filings
· $32.2M notice value
· 5 unique filers
· 91% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
Farquhar John C.M. (7, $9.4M) · Cohen Arthur Bruce (1, $8.4M) · Healey Joseph Patrick (1, $6.2M) · Verghese Vikram (8, $4.9M) · Rogers Campbell (5, $3.3M)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-11-10 | Farquhar John C.M. | Officer, Director | 38,900 | $2.17M | 2026-11-10 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-11-09 | Verghese Vikram | Officer | 3,587 | $190.6K | 2026-11-09 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-10-22 | Rogers Campbell | Officer | 23,933 | $1.32M | 2026-10-22 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-10-22 | Rogers Campbell | Member of immediate family of any of the foregoing | 5,654 | $311.0K | 2026-10-22 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-10-13 | Farquhar John C.M. | Officer, Director | 38,900 | $1.93M | 2026-10-12 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-09-18 | Verghese Vikram | Officer | 16,766 | $850.9K | 2026-09-18 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-09-18 | Rogers Campbell | Member of immediate family of any of the foregoing | 5,653 | $283.5K | 2026-09-18 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-09-18 | Rogers Campbell | Officer | 19,682 | $987.1K | 2026-09-18 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-09-17 | Verghese Vikram | Officer | 7,579 | $379.8K | 2026-09-17 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
| 2026-09-15 | Verghese Vikram | Officer | 668 | $33.4K | 2026-09-15 | Fidelity Brokerage Services LLC | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-08-13
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-08-13 | 0001464521-26-000131 | EDGAR |
ETF Holders
55 ETFs hold HTFL
25 shown · $563.98M total exposure · 0.09% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.01% | $123.4M | — | 2026-09-30 |
| 2 | IWM iShares Russell 2000 ETF | iShares (BlackRock) | 0.14% | $113.5M | $77.8B | 2026-11-09 |
| 3 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.05% | $87.7M | — | 2026-09-30 |
| 4 | VBR Vanguard Morningstar Small-Cap Value ETF | Vanguard | 0.09% | $57.0M | — | 2026-09-30 |
| 5 | IWO iShares Russell 2000 Growth ETF | iShares (BlackRock) | 0.29% | $41.1M | $14.1B | 2026-11-09 |
| 6 | VXF Vanguard Extended Market ETF | Vanguard | 0.04% | $37.6M | — | 2026-09-30 |
| 7 | VTWO Vanguard Russell 2000 ETF | Vanguard | 0.13% | $22.2M | — | 2026-09-30 |
| 8 | FESM Fidelity Enhanced Small Cap Core ETF | Fidelity | 0.25% | $17.1M | $6.8B | 2026-11-09 |
| 9 | VHT Vanguard Health Care ETF | Vanguard | 0.05% | $10.2M | — | 2026-09-30 |
| 10 | FYC First Trust Small Cap Growth AlphaDEX® Fund | First Trust | 0.72% | $9.9M | $1.4B | 2026-11-09 |
| 11 | IHF iShares U.S. Healthcare Providers ETF | iShares (BlackRock) | 0.47% | $7.2M | $1.6B | 2026-11-09 |
| 12 | ITOT iShares Core S&P Total U.S. Stock Market ETF | iShares (BlackRock) | 0.01% | $5.2M | $95.3B | 2026-11-09 |
| 13 | FYX First Trust Small Cap Core AlphaDEX® Fund | First Trust | 0.34% | $4.8M | $1.4B | 2026-11-09 |
| 14 | SCHA Schwab U.S. Small-Cap ETF | Nport | 0.02% | $4.4M | — | 2026-08-31 |
| 15 | VTWG Vanguard Russell 2000 Growth ETF | Vanguard | 0.25% | $4.2M | — | 2026-09-30 |
| 16 | SMLF iShares U.S. Small-Cap Equity Factor ETF | iShares (BlackRock) | 0.07% | $3.1M | $4.3B | 2026-11-09 |
| 17 | FBCG Fidelity Blue Chip Growth ETF | Nport | 0.04% | $2.7M | — | 2026-07-31 |
| 18 | RSSL Global X Russell 2000 ETF | Global X | 0.14% | $2.1M | — | 2026-11-10 |
| 19 | FHLC Fidelity MSCI Health Care Index ETF | Fidelity | 0.05% | $2.0M | $4.1B | 2026-11-09 |
| 20 | FPX First Trust US Equity Opportunities ETF | First Trust | 0.15% | $1.9M | $1.3B | 2026-11-09 |
| 21 | ESML iShares ESG Aware MSCI USA Small-Cap ETF | iShares (BlackRock) | 0.07% | $1.8M | $2.8B | 2026-11-09 |
| 22 | ISCG iShares Morningstar Small-Cap Growth ETF | iShares (BlackRock) | 0.14% | $1.4M | $961.6M | 2026-11-09 |
| 23 | VFMO Vanguard U.S. Momentum Factor ETF | Vanguard | 0.07% | $1.3M | — | 2026-11-09 |
| 24 | ONEQ Fidelity Nasdaq Composite Index ETF | Fidelity | 0.01% | $1.3M | $10.4B | 2026-11-09 |
| 25 | IWV iShares Russell 3000 ETF | iShares (BlackRock) | 0.01% | $1.2M | $20.3B | 2026-11-09 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
—
TTM Diluted EPS
$-1.52
TTM Revenue
$191.42M
TTM Net Income
$-111.83M
TTM Op. Cash Flow
$-56.82M
Quarterly figures (3 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q1 '26 | 2026-03-31 | $52.59M | $-27.38M | $-0.32 | $-30.10M |
| Q4 '25 | 2025-12-31 | $49.13M | $-24.39M | $1.30 | $-10.60M |
| Q3 '25 | 2025-09-30 | $46.28M | $-50.85M | $-1.04 | $-2.96M |
Q1 2026 • period ending 2026-03-31 • filed 2026-05-14
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
—
P/B
8.94
P/S
13.34
EV/EBITDA
—
EV/Sales
13.24
ROE
-39.1%
ROA
-32.5%
Div Yield
0.00%
FCF Yield
-2.22%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$2.55B
as of 2026-11-11
HTFL vs Peers
Related companies, largest first| Company | Market cap | P/E | Revenue growth | YTD | IV rank |
|---|---|---|---|---|---|
| ISRG Intuitive Surgical Inc. | $159.7B | 54.1 | +20.5% | −20.3% | 17 |
| NTRA Natera, Inc. Common Stock | $46.5B | — | +36.6% | +39.0% | 35 |
| RVMD Revolution Medicines, Inc. Common Stock | $43.3B | — | — | +142.1% | 57 |
| RMD ResMed Inc. | $33.2B | 21.3 | +9.0% | −4.3% | 20 |
| DXCM DexCom, Inc. | $30.2B | 31.4 | +13.0% | +19.9% | 33 |
| GH Guardant Health, Inc. Common Stock | $21.5B | — | +42.7% | +57.9% | 22 |
| OSCR Oscar Health, Inc. | $10.0B | — | +32.3% | +121.3% | 0 |
| TWST Twist Bioscience Corporation Common Stoc | $9.0B | — | +17.8% | +329.5% | 85 |
| HTFL Heartflow, Inc. Common Stock | $4.9B | — | — | +97.1% | 100 |
| Peer median | $31.7B | 31.4 | +20.5% | +48.4% | 27 |
P/E uses the latest reported trailing-12-month diluted EPS; "—" means no positive earnings or no data.
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
7.33M
SI % of Float
10.62%
Days to Cover
4.42
Short Vol Ratio
45.3%
Free Float
69.01M
Float %
80.0%
Short interest 2026-10-15 • Short volume 2026-11-10 • Float 2026-09-22